Table 3.

Headache characteristics during erenumab treatment vs. baseline (4 weeks before erenumab treatment).

	Weeks 1–4	Weeks 5–8	Weeks 9–12
MHD (baseline)	14.0 ± 8.3 (17.7 ± 6.8)	13.4 ± 8.6 (18.7 ± 6.9)	13.9 ± 8.5 (18.6 ± 6.8)
Reduction from baseline	−3.7 ± 5.5	−5.3 ± 5.4	−4.7 ± 5.9
N	68	60	45
P	<0.001	<0.001	<0.001
MMD (baseline)	10.5 ± 6.4 (14.6 ± 5.3)	10.4 ± 6.7 (15.3 ± 6.0)	10.9 ± 6.4 (15.4 ± 5.0)
Reduction from baseline	−4.0 ± 5.5	−4.9 ± 4.4	−4.5 ± 4.6
N	43	38	23
P	<0.001	<0.001	<0.001
MDSH (baseline)	3.4 ± 4.3 (6.7 ± 5.8)	3.7 ± 4.7 (7.0 ± 6.3)	3.3 ± 4.3 (7.6 ± 5.4)
Reduction from baseline	−3.3 ± 4.4	−3.3 ± 4.1	−4.3 ± 4.7
N	29	23	13
P	0.004	0.015	0.09
AMD (Baseline)	7.0 ± 4.4 (11.9 ± 4.6)	7.0 ± 4.3 (12.3 ± 5.7)	6.5 ± 2.9 (12.8 ± 5.0)
Reduction from baseline	−4.9 ± 4.0	−5.3 ± 5.2	−6.3 ± 4.8
N	43	35	22
P	<0.001	<0.001	<0.001
TriD (Baseline)	6.6 ± 5.7 (10.7 ± 5.9)	5.1 ± 4.0 (10.3 ± 6.9)	5.6 ± 2.8 (10.3 ± 6.2)
Reduction from baseline	−4.1 ± 4.1	−5.2 ± 6.1	−4.7 ± 4.6
N	45	39	27
P	<0.001	<0.001	<0.001

MHD, monthly headache days; MMD, monthly migraine days; MDSH. monthly days with severe headache; AMD, monthly days with acute medication use; TriD, monthly days with triptan use; n, patients in the respective category with available data for analysis; p, Bonferroni adjusted p-value for multiple (=15) comparisons. Data are reported as mean ± standard deviation.